Abstract

Fostamatinib blocks spleen tyrosine kinase, which plays a key role in antibody-mediated cellular responses, thereby reducing antibody-mediated destruction of platelets. Expected benefits include an increase and maintenance of platelet count and reduction in bleeding risk.